BIVV News - Candlesense

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fati...

What is the anticipated pricing and reimbursement strategy for Beziterim if approved? How does this trial compare to competitor pipelines targeting Long COVID or related post‑acute infection syndromes? What are the key risks if the trial fails to meet its endpoints?

Clinical trials

10 days ago